Moderna stock pharmaceuticals stock reacting to strong imbalances

Moderna stock MRNA pharmaceutical has started to react to the strong weekly imbalance mentioned in the last update. This biotech company is distributing one of the approved coronavirus vaccines to millions of people around the world. Is Moderna stock MRNA a stock to buy? It definitely has been, as explained in the last Moderna stock analysis.

Moderna stock has been a stock to buy quite a few times in the last few months. As supply and demand traders, we should focus on clear buying imbalances. We have analyzed in depth Moderna pharmaceuticals stock in Set and Forget’s the online trading academy.

Moderna (MRNA) joined Pfizer (PFE) and partnered with BioNTech (BNTX) to have a COVID-19 vaccine authorized in December 2020. Both vaccines use messenger RNA technology to prompt an immune response. Johnson & Johnson (JNJ) followed with its own authorization in February 2021.

Moderna Pharmaceuticals prediction

Below we can see the weekly timeframe for Moderna stock. We can see two strong weekly demand imbalances around $122 and $103. The imbalances at $103 and $122 per share have played out nicely as called in Set and Forget’s online trading academy. The second imbalance at $122 is playing out as expected. This is trading in hindsight or after the fact. These trades were planned weeks before the price pulled back to those price levels. That’s what we do at Set and Forget’s online trading academy.

Shares of Moderna stock hit a record high on Feb 2021. The stock popped up and down for a few weeks, respecting the imbalances you can see on the chart below. The last two weekly imbalances on Moderna stock MRNA are playing out as expected. There is no reason to get rid of the shares with a clear uptrend and bullish bias.

Moderna MRNA Stock, price action analysis, using supply and demand strategy

This is the kind of price action technical analysis you will learn in our trading community. You will learn how to locate new supply and demand imbalances and trade without using any indicators, no news, no fundamental analysis, no earnings announcements, no volume or VSA analysis. Just supply and demand imbalances on Moderna MRNA stock.

Trading supply and demand imbalances are ideal for beginners and those with a full or half time job, you won’t need to stay in front of the computer all day long trying to move price action with your mind. 

As supply and demand traders, we do not need to pay attention to the news, fundamentals or any earnings reports. Once a big timeframe imbalance has gained control, earnings do just the opposite and react strongly to those imbalances. Why do you see positive earnings and then the underlying stock drops like a rock? Or a negative earnings announcement and the stock rallies like a rocket out of control? You are probably missing the fact that there are big imbalances in gaining control.

Unless you are doing very short-term trading and scalping, you should not worry about fundamentals or earnings announcements on Moderna MRNA stock. Join our supply and demand stock trading course to learn how to use our supply and demand trading strategy.